N-Acetyl Semax Amidate vs Semax: What Do the Modifications Change?

Quick answer: Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone. N-acetyl Semax amidate is the same seven-residue sequence with both ends capped: an acetyl group on the N-terminus and an amide in place of the C-terminal carboxylic acid. The caps remove both terminal charges and are intended to slow breakdown by exopeptidases. Almost all published research was conducted with unmodified Semax; direct, peer-reviewed comparisons of the two forms are scarce.

This article explains what the modifications change chemically, what is and is not established in the literature, and how the two compounds differ at the bench. For laboratory research use only; not for human consumption.

What is Semax?

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its design starts from ACTH(4-7), the Met-Glu-His-Phe fragment of adrenocorticotropic hormone, which earlier work had shown to retain behavioral activity in animal models without the hormone's adrenal effects. To that fragment the developers attached the tripeptide Pro-Gly-Pro at the C-terminus. Proline-rich sequences resist many peptidases, and the PGP tail was added to lengthen the fragment's survival in biological fluids.

The resulting heptapeptide has the formula C₃₇H₅₁N₉O₁₀S and a molecular weight of about 813.9 g/mol. It lacks the hormonal (steroidogenic) activity of full-length ACTH. The unmodified peptide is stocked as a 10 mg vial: Semax.

What is N-acetyl Semax amidate?

N-acetyl Semax amidate (often abbreviated NASA or NA-Semax-amidate) keeps the same amino acid sequence and adds two terminal modifications that are standard tools in peptide chemistry:

• N-terminal acetylation: the free amine of the methionine residue is converted to an acetamide (CH₃CO–NH–).
• C-terminal amidation: the terminal carboxylic acid of the final proline is converted to a primary amide (–CONH₂).

The written sequence becomes Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂, with the formula C₃₉H₅₄N₁₀O₁₀S and a molecular weight of about 855.0 g/mol, roughly 41 Da heavier than the parent.

N-acetyl Semax amidate vs Semax at a glance

What the terminal caps change

Resistance to exopeptidases

Peptide breakdown in serum and tissue is driven in large part by exopeptidases, enzymes that remove residues one or two at a time from a free end. Aminopeptidases need a free N-terminal amine to engage their substrate; carboxypeptidases need a free C-terminal carboxylate. Acetylation and amidation remove those recognition features. This is the same logic used across peptide research, and many endogenous neuropeptides are naturally amidated or acetylated for that reason.

The relevance to Semax is specific. Degradation studies of the unmodified peptide in rat serum and brain membrane preparations show that breakdown proceeds mainly from the N-terminus: loss of methionine gives Glu-His-Phe-Pro-Gly-Pro, and further trimming yields His-Phe-Pro-Gly-Pro and ultimately Pro-Gly-Pro. Since the dominant route is aminopeptidase-driven, an N-terminal acetyl cap is a rational way to slow it. The C-terminal PGP sequence was already relatively protected, so the amide is likely to contribute less.

Charge and polarity

Unmodified Semax is a zwitterion at its termini, with a positive amine at one end and a negative carboxylate at the other. Capping removes both charges. The net charge is essentially unchanged, because one positive and one negative charge are lost together, but the molecule has fewer ionized groups overall and is somewhat more lipophilic. In general peptide chemistry, lower charge density is associated with greater passive membrane permeability, though the size of that effect for this particular peptide has not been quantified in published work.

Fragments and metabolites

One subtle point is easy to overlook. Some of the biological activity attributed to Semax may involve its breakdown products; Pro-Gly-Pro and related fragments are themselves studied as bioactive peptides. A capped analog that is degraded more slowly, or along a different route, could generate a different mix of fragments over time. That makes the two compounds non-interchangeable in experiments where metabolite formation matters.

What the published research covers

Semax

The parent peptide has a sizeable preclinical literature, most of it in rats and in cultured neural cells:

• Neurotrophin expression: intranasal application in rats was reported to increase BDNF protein and mRNA for its receptor TrkB in the hippocampus, alongside specific binding sites for labeled Semax in basal forebrain membranes.
• Transcriptomic studies: in rat models of focal cerebral ischemia, Semax altered the expression of large gene sets related to immune response and vascular function.
• Monoamine systems: rodent microdialysis and tissue studies describe effects on dopaminergic and serotonergic turnover.
• Melanocortin receptors and enzymes: the peptide has been examined for interaction with melanocortin receptor subtypes and for inhibition of enkephalin-degrading enzymes in vitro.

N-acetyl Semax amidate

By contrast, peer-reviewed studies that characterize the capped analog, or that compare it head-to-head with Semax in the same assay, are hard to find. Statements that the amidate form is "stronger" or "longer lasting" are, at present, inferences from general peptide chemistry and from the known degradation route of the parent molecule. They are reasonable hypotheses, but they are not established measurements. Laboratories working with the capped form should plan to generate their own stability and activity data alongside an unmodified Semax control.

Laboratory handling

Both compounds are short, lyophilized peptides handled in the same general way.

• Reconstitution math: adding 2 mL of diluent to a 10 mg vial gives 5 mg/mL. On a molar basis that is about 6.14 mM for Semax (813.9 g/mol) and about 5.85 mM for the capped analog (855.0 g/mol). Equal masses of the two therefore do not contain equal moles; the difference is roughly 5%. The calculator can verify stock concentrations.
• Technique: introduce diluent slowly against the vial wall and swirl gently, as described in how to mix peptides with bacteriostatic water.
• Methionine oxidation: both peptides contain an N-terminal methionine, whose thioether side chain oxidizes to the sulfoxide (+16 Da) on exposure to air, light and trace metals. Capping the termini does not protect the side chain. Minimize headspace, avoid prolonged time at room temperature, and protect solutions from light.
• Storage: lyophilized vials at −20 °C; reconstituted solutions at 2–8 °C, or frozen in single-use aliquots. General guidance is in storing research peptides.

Telling the two apart analytically

The two compounds are easily distinguished by mass spectrometry. Unmodified Semax gives an [M+H]⁺ ion near m/z 814.9, while the acetylated, amidated analog appears near m/z 856.0. On reversed-phase HPLC the capped form generally elutes later because it is less polar. A certificate of analysis reporting both the observed mass and chromatographic purity removes any ambiguity; batch documents are published on the COA page.

Designing a head-to-head comparison

Because comparative data are thin, a laboratory interested in the capped analog is effectively generating primary evidence. A few design points make that evidence more useful:

• Match by moles, not mass. Prepare both stocks to the same molar concentration so that any difference in response is not an artifact of the 5% molecular-weight gap.
• Measure stability directly. Incubate each peptide in the relevant matrix, such as serum, plasma or tissue homogenate, and quantify the intact parent by LC-MS at fixed time points.
• Track fragments. Monitor for the des-Met hexapeptide, the pentapeptide and Pro-Gly-Pro, since the pattern of metabolites may differ between the two forms.
• Control for oxidation. Include a check for the methionine sulfoxide species so that oxidative loss is not mistaken for enzymatic breakdown.

Choosing a compound for a study

• Use Semax when the aim is to replicate or extend published findings, since the existing literature was generated with the unmodified peptide.
• Consider N-acetyl Semax amidate when the research question is itself about terminal capping, such as comparative stability in serum or tissue homogenate, permeability assays, or metabolite profiling.
• Run both side by side, at matched molar concentrations, when the goal is to attribute a difference to the modifications.

Related neuropeptides such as Selank, which shares the Pro-Gly-Pro stabilizing motif, are listed with the full catalog in the shop. For background on the category, see what research peptides are.

Frequently asked questions

Is N-acetyl Semax amidate the same peptide as Semax?

It has the same seven-residue sequence, but it is a chemically distinct compound. The N-terminus is acetylated and the C-terminus is amidated, which changes the molecular formula, raises the molecular weight by about 41 Da, and removes both terminal charges.

Why are the terminal caps added?

Capping blocks the free amine and free carboxylate that exopeptidases use to recognize peptide ends. Because unmodified Semax is known to be degraded mainly from its N-terminus, the acetyl cap in particular is expected to slow that process.

Is there published evidence that the amidate form is more potent?

Not in the peer-reviewed literature in any robust, head-to-head form. Published mechanistic and animal studies were performed with unmodified Semax. Claims about the capped analog rest on chemical reasoning and should be regarded as hypotheses to be tested.

Does capping prevent methionine oxidation?

No. Oxidation occurs on the methionine side chain, which is unaffected by acetylation of the backbone amine. Both forms should be protected from air, light and heat, and both can show a +16 Da oxidation product on mass spectrometry if mishandled.